Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Down 7.1% in September

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 1,040,000 shares, a decrease of 7.1% from the September 15th total of 1,120,000 shares. Currently, 3.4% of the company’s stock are sold short. Based on an average trading volume of 184,400 shares, the short-interest ratio is presently 5.6 days.

Werewolf Therapeutics Trading Down 0.5 %

NASDAQ:HOWL opened at $2.05 on Friday. The company has a market capitalization of $89.08 million, a P/E ratio of -1.88 and a beta of 0.45. The company has a current ratio of 12.13, a quick ratio of 12.13 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 12 month low of $1.57 and a 12 month high of $8.19. The firm has a fifty day simple moving average of $2.11 and a 200-day simple moving average of $3.37.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%. The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. On average, equities research analysts anticipate that Werewolf Therapeutics will post -1.64 earnings per share for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new position in shares of Werewolf Therapeutics during the first quarter worth $10,922,000. Millennium Management LLC raised its stake in shares of Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after buying an additional 544,881 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock valued at $1,119,000 after buying an additional 94,212 shares during the period. Vanguard Group Inc. boosted its stake in shares of Werewolf Therapeutics by 26.8% in the first quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after buying an additional 233,909 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Werewolf Therapeutics by 103.1% during the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after acquiring an additional 86,800 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.